KHK and metabolic dysfunction-associated steatotic liver disease: These findings indicate that saroglitazar and ferulic acid may effectively suppress KHK activity, thereby providing therapeutic benefits for metabolic illnesses such as metabolic dysfunction-associated steatotic liver disease (MASLD).